MERIT - A Phase II Marker Identification Trial for Tarceva in Second Line NSCLC Patients
收藏DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00005803/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This study will assess potentially predictive markers of efficacy in participants with NSCLC receiving oral erlotinib (Tarceva) therapy. The anticipated time on study treatment is until disease progression, unacceptable toxicity or death.
提供机构：
Vivli
创建时间：
2020-05-05
